Exploring the links between Obesity and Psoriasis: A comprehensive review
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | eng |
| dc.contributor.author | Barros, Gabriela | |
| dc.contributor.author | Duran, Pablo | |
| dc.contributor.author | Vera, Ivana | |
| dc.contributor.author | Bermúdez, Valmore | |
| dc.date.accessioned | 2022-11-16T16:38:46Z | |
| dc.date.available | 2022-11-16T16:38:46Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Obesity is a major public health issue worldwide since it is associated with the development of chronic comorbidities such as type 2 diabetes, dyslipidemias, atherosclerosis, some cancer forms and skin diseases, including psoriasis. Scientific evidence has indicated that the possible link between obesity and psoriasis may be multifactorial, highlighting dietary habits, lifestyle, certain genetic factors and the microbiome as leading factors in the progress of both pathologies because they are associated with a chronic pro-inflammatory state. Thus, inflammation management in obesity is a plausible target for psoriasis, not only because of the sick adipose tissue secretome profile but also due to the relationship of obesity with the rest of the immune derangements associated with psoriasis initiation and maintenance. Hence, this review will provide a general and molecular overview of the relationship between both pathologies and present recent therapeutic advances in treating this problem. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.citation | Barros, G., Duran, P., Vera, I., & Bermúdez, V. (2022). Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. International Journal of Molecular Sciences, 23(14), 7499. https://doi.org/10.3390/ijms23147499 | eng |
| dc.identifier.doi | https://doi.org/10.3390/ijms23147499 | |
| dc.identifier.issn | 14220067 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/11331 | |
| dc.language.iso | eng | eng |
| dc.publisher | MDPI | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | International Journal of Molecular Sciences | eng |
| dc.source | Vol. 23, Issue 14 (2022) | eng |
| dc.subject | adipokines | eng |
| dc.subject | cytokines | eng |
| dc.subject | inflammation | eng |
| dc.subject | Obesity | eng |
| dc.subject | Psoriasis | eng |
| dc.subject | microbiota | eng |
| dc.subject | Body Mass Index | eng |
| dc.title | Exploring the links between Obesity and Psoriasis: A comprehensive review | eng |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Jensen, P.; Skov, L. Psoriasis and Obesity. Dermatology 2016, 232, 633–639. | eng |
| dcterms.references | Su, X.; Cheng, Y.; Chang, D. The Important Role of Leptin in Modulating the Risk of Dermatological Diseases. Front. Immunol. 2021, 11, 593564. | eng |
| dcterms.references | Kanda, N.; Hoashi, T.; Saeki, H. Nutrition and Psoriasis. Int. J. Mol. Sci. 2020, 21, 5405 | eng |
| dcterms.references | Bonanad, C.; González-Parra, E.; Rivera, R.; Carrascosa, J.M.; Daudén, E.; Olveira, A.; Botella-Estrada, R. Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. Actas Dermosifiliogr. 2017, 108, 800–808. | eng |
| dcterms.references | Timmins, K.A.; Leech, R.D.; Batt, M.E.; Edwards, K.L. Running and Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am. J. Sports Med. 2017, 45, 1447–1457. | eng |
| dcterms.references | Ye, Q.; Zou, B.; Yeo, Y.H.; Li, J.; Huang, D.Q.; Wu, Y.; Yang, H.; Liu, C.; Kam, L.Y.; Tan, X.X.E.; et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020, 5, 739–752. | eng |
| dcterms.references | Luppino, F.S.; de Wit, L.M.; Bouvy, P.F.; Stijnen, T.; Cuijpers, P.; Penninx, B.W.J.H.; Zitman, F.G. Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 2010, 67, 220–229 | eng |
| dcterms.references | Cortese, S.; Tessari, L. Attention-Deficit/Hyperactivity Disorder (ADHD) and Obesity: Update 2016. Curr. Psychiatry Rep. 2017, 19, 4. | eng |
| dcterms.references | Kelishadi, R.; Roufarshbaf, M.; Soheili, S.; Payghambarzadeh, F.; Masjedi, M. Association of Childhood Obesity and the Immune System: A Systematic Review of Reviews. Child. Obes. 2017, 13, 332–346. | eng |
| dcterms.references | Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298. | eng |
| dcterms.references | Carretero, J.; Ena, J.; Arévalo, J.C.; Seguí, J.M.; Carrasco, F.J.; Gómez, R.; Pérez, M.I.; Delgado, J.; Pérez, P. Obesity is a chronic disease. Positioning statement of the Diabetes, Obesity and Nutrition Workgroup of the Spanish Society of Internal Medicine (SEMI) for an approach centred on individuals with obesity. Rev. Clínica Esp. 2021, 221, 509–516. | eng |
| dcterms.references | Pan, X.-F.; Wang, L.; Pan, A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021, 9, 373–392. | eng |
| dcterms.references | CDC CDC Overweight & Obesity. Centers for Disease Control and Prevention. 2021. Available online: https://www.cdc.gov/obesity/index.html | eng |
| dcterms.references | Orloff, J.; Kaminetsky, J.; Aziz, M. Psoriasis and Obesity: A Review of the Current Literature. SKIN J. Cutan. Med. 2018, 2, 364–379. | eng |
| dcterms.references | Chooi, Y.C.; Ding, C.; Magkos, F. The epidemiology of obesity. Metabolism 2019, 92, 6–10. | eng |
| dcterms.references | An, R.; Ji, M.; Zhang, S. Global warming and obesity: A systematic review. Obes. Rev. 2018, 19, 150–163. | eng |
| dcterms.references | Jaacks, L.M.; Vandevijvere, S.; Pan, A.; McGowan, C.J.; Wallace, C.; Imamura, F.; Mozaffarian, D.; Swinburn, B.; Ezzati, M. The obesity transition: Stages of the global epidemic. Lancet Diabetes Endocrinol. 2019, 7, 231–240. | eng |
| dcterms.references | Nga, V.T.; Dung, V.N.T.; Chu, D.-T.; Tien, N.L.B.; Van Thanh, V.; Ngoc, V.T.N.; Hoan, L.N.; Phuong, N.T.; Pham, V.-H.; Tao, Y.; et al. School education and childhood obesity: A systemic review. Diabetes Metab. Syndr. 2019, 13, 2495–2501. | eng |
| dcterms.references | Koch, C.A.; Sharda, P.; Patel, J.; Gubbi, S.; Bansal, R.; Bartel, M.J. Climate Change and Obesity. Horm. Metab. Res. 2021, 53, 575–587. | eng |
| dcterms.references | Dhurandhar, E.J. The food-insecurity obesity paradox: A resource scarcity hypothesis. Physiol. Behav. 2016, 162, 88–92. | eng |
| dcterms.references | Figueira, T.C.F.; Corrente, J.E.; Miot, L.D.B.; Papini, S.J.; Miot, H.A. Dietary patterns of patients with psoriasis at a public healthcare institution in Brazil. An. Bras. Dermatol. 2020, 95, 452–458. | eng |
| dcterms.references | Chen, G.; Chen, Z.-M.; Fan, X.-Y.; Jin, Y.-L.; Li, X.; Wu, S.-R.; Ge, W.-W.; Lv, C.-H.; Wang, Y.-K.; Chen, J.-G. Gut-Brain-Skin Axis in Psoriasis: A Review. Derm. Ther. 2021, 11, 25–38. | eng |
| dcterms.references | Liakou, A.; Zouboulis, C. Links and risks associated with psoriasis and metabolic syndrome. Psoriasis Targets Ther. 2015, 5, 125. | eng |
| dcterms.references | Langan, S.M.; Seminara, N.M.; Shin, D.B.; Troxel, A.B.; Kimmel, S.E.; Mehta, N.N.; Margolis, D.J.; Gelfand, J.M. Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. J. Investig. Dermatol. 2012, 132, 556–562. | eng |
| dcterms.references | Gisondi, P.; Fostini, A.C.; Fossà, I.; Girolomoni, G.; Targher, G. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018, 36, 21–28. | eng |
| dcterms.references | Larabi, A.; Barnich, N.; Nguyen, H.T.T. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy 2020, 16, 38–51. | eng |
| dcterms.references | Safari, Z.; Gérard, P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol. Life Sci. 2019, 76, 1541–1558. | eng |
| dcterms.references | Megur, A.; Baltriukienė, D.; Bukelskienė, V.; Burokas, A. The Microbiota-Gut-Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame? Nutrients 2020, 13, 37. | eng |
| dcterms.references | Myers, B.; Brownstone, N.; Reddy, V.; Chan, S.; Thibodeaux, Q.; Truong, A.; Bhutani, T.; Chang, H.-W.; Liao, W. The gut microbiome in psoriasis and psoriatic arthritis. Best Pract. Res. Clin. Rheumatol. 2019, 33, 101494. | eng |
| dcterms.references | Verhaar, B.J.H.; Prodan, A.; Nieuwdorp, M.; Muller, M. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients 2020, 12, 2982. | eng |
| dcterms.references | Armstrong, A.W.; Read, C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020, 323, 1945–1960. | eng |
| dcterms.references | Liang, Y.; Sarkar, M.K.; Tsoi, L.C.; Gudjonsson, J.E. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017, 49, 1–8. | eng |
| dcterms.references | Kunz, M.; Simon, J.C.; Saalbach, A. Psoriasis: Obesity and Fatty Acids. Front. Immunol. 2019, 10, 1807. | eng |
| dcterms.references | Kim, H.-N.; Han, K.; Park, Y.-G.; Lee, J.H. Metabolic syndrome is associated with an increased risk of psoriasis: A nationwide population-based study. Metabolism 2019, 99, 19–24 | eng |
| dcterms.references | Kyriakou, A.; Patsatsi, A.; Sotiriadis, D.; Goulis, D.G. Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: A systematic review and meta-analysis. Br. J. Derm. 2018, 179, 273–281. | eng |
| dcterms.references | Ogawa, K.; Stuart, P.E.; Tsoi, L.C.; Suzuki, K.; Nair, R.P.; Mochizuki, H.; Elder, J.T.; Okada, Y. A Transethnic Mendelian Randomization Study Identifies Causality of Obesity on Risk of Psoriasis. J. Investig. Dermatol. 2019, 139, 1397–1400. | eng |
| dcterms.references | Verdugo, A. Prevalencia de sobrepeso y obesidad en adultos de la ciudad de Cuenca-Ecuador, 2014. Rev. Fac. Cienc. Méd. Univ. Cuenca 2018, 36, 54–60. | eng |
| dcterms.references | Hirt, P.A.; Castillo, D.E.; Yosipovitch, G.; Keri, J.E. Skin changes in the obese patient. J. Am. Acad. Dermatol. 2019, 81, 1037–1057. | eng |
| dcterms.references | Paroutoglou, K.; Papadavid, E.; Christodoulatos, G.S.; Dalamaga, M. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. Curr. Obes. Rep. 2020, 9, 165–178. | eng |
| dcterms.references | Kong, Y.; Zhang, S.; Wu, R.; Su, X.; Peng, D.; Zhao, M.; Su, Y. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019, 18, 171. | eng |
| dcterms.references | Stjernholm, T.; Ommen, P.; Langkilde, A.; Johansen, C.; Iversen, L.; Rosada, C.; Stenderup, K. Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Exp. Derm. 2017, 26, 338–345. | eng |
| dcterms.references | Snekvik, I.; Smith, C.H.; Nilsen, T.I.L.; Langan, S.M.; Modalsli, E.H.; Romundstad, P.R.; Saunes, M. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J. Investig. Dermatol. 2017, 137, 2484–2490. | eng |
| dcterms.references | Kumar, S.; Han, J.; Li, T.; Qureshi, A.A. Obesity, waist circumference, weight change and the risk of psoriasis in US women: Risk of psoriasis in US women. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 1293–1298. | eng |
| dcterms.references | Ko, S.-H.; Chi, C.-C.; Yeh, M.-L.; Wang, S.-H.; Tsai, Y.-S.; Hsu, M.-Y. Lifestyle changes for treating psoriasis. Cochrane Database Syst. Rev. 2019, 7, 1–68. | eng |
| dcterms.references | Lebwohl, M.G. Psoriasis: Which therapy for which patient. J. Am. Acad. Dermatol. 2019, 80, 27–40. | eng |
| dcterms.references | Dopytalska, K.; Baranowska-Bik, A.; Roszkiewicz, M.; Bik, W.; Walecka, I. The role of leptin in selected skin diseases. Lipids Health Dis. 2020, 19, 215. | eng |
| dcterms.references | Tollefson, M.M.; Crowson, C.S.; McEvoy, M.T.; Maradit Kremers, H. Incidence of psoriasis in children: A population-based study. J. Am. Acad. Dermatol. 2010, 62, 979–987. | eng |
| dcterms.references | Castaldo, G.; Rastrelli, L.; Galdo, G.; Molettieri, P.; Rotondi Aufiero, F.; Cereda, E. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition 2020, 74, 110757. | eng |
| dcterms.references | Llamas-Velasco, M.; Ovejero-Merino, E.; Salgado-Boquete, L. Obesidad: Factor de riesgo para psoriasis y COVID-19. Actas Dermo-Sifiliográficas 2020, 112, 489–494. | eng |
| dcterms.references | Takeshita, J.; Grewal, S.; Langan, S.M.; Mehta, N.N.; Ogdie, A.; Van Voorhees, A.S.; Gelfand, J.M. Psoriasis and comorbid diseases. J. Am. Acad. Dermatol. 2017, 76, 377–390. | eng |
| dcterms.references | Vanderpuye-Orgle, J.; Zhao, Y.; Lu, J.; Shrestha, A.; Sexton, A.; Seabury, S.; Lebwohl, M. Evaluating the economic burden of psoriasis in the United States. J. Am. Acad. Derm. 2015, 72, 961–967.e5. | eng |
| dcterms.references | Parisi, R.; Iskandar, I.Y.K.; Kontopantelis, E.; Augustin, M.; Griffiths, C.E.M.; Ashcroft, D.M. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ 2020, 369, m1590. | eng |
| dcterms.references | Icen, M.; Crowson, C.S.; McEvoy, M.T.; Dann, F.J.; Gabriel, S.E.; Maradit Kremers, H. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. J. Am. Acad. Dermatol. 2009, 60, 394–401. | eng |
| dcterms.references | Prevalence of Psoriasis in Italy 2010–2017. Statista. Available online: https://www.statista.com/statistics/944680/prevalence-of-psoriasis-in-italy/ (accessed on 22 October 2021). | eng |
| dcterms.references | Ortega, F.B.; Lavie, C.J.; Blair, S.N. Obesity and Cardiovascular Disease. Circ. Res. 2016, 118, 1752–1770. | eng |
| dcterms.references | Xie, W.; Huang, H.; Deng, X.; Gao, D.; Zhang, Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies. J. Am. Acad. Derm. 2021, 84, 701–711. | eng |
| dcterms.references | Hsu, S.; Green, L.J.; Lebwohl, M.G.; Wu, J.J.; Blauvelt, A.; Jacobson, A.A. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: Analysis of two randomized controlled trials. Br. J. Derm. 2020, 182, 880–888. | eng |
| dcterms.references | Norden, A.; Rekhtman, S.; Strunk, A.; Garg, A. Risk of psoriasis according to body mass index: A retrospective cohort analysis. J. Am. Acad. Dermatol. 2021, 86, 1020–1026. | eng |
| dcterms.references | Karmacharya, P.; Ogdie, A.; Eder, L. Psoriatic arthritis and the association with cardiometabolic disease: A narrative review. Adv. Musculoskelet. Dis. 2021, 13, 1759720X21998279. | eng |
| dcterms.references | Bavoso, N.C.; Pinto, J.M.; Soares, M.M.S.; dos Santos Diniz, M.; Teixeira Júnior, A.L. Psoriasis in obesity: Comparison of serum levels of leptin and adiponectin in obese subjects—Cases and controls. An. Bras. Dermatol. 2019, 94, 192–197. | eng |
| dcterms.references | Chen, L.; Li, J.; Zhu, W.; Kuang, Y.; Liu, T.; Zhang, W.; Chen, X.; Peng, C. Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies. Front. Microbiol. 2020, 11, 589726. | eng |
| dcterms.references | Setty, A.R. Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses’ Health Study II. Arch. Intern. Med. 2007, 167, 1670–1675. | eng |
| dcterms.references | Hidalgo-Cantabrana, C.; Gómez, J.; Delgado, S.; Requena-López, S.; Queiro-Silva, R.; Margolles, A.; Coto, E.; Sánchez, B.; Coto-Segura, P. Gut microbiota dysbiosis in a cohort of patients with psoriasis. Br. J. Derm. 2019, 181, 1287–1295. | eng |
| dcterms.references | Heitmann, J.; Frings, V.G.; Geier, A.; Goebeler, M.; Kerstan, A. Non-alcoholic fatty liver disease and psoriasis—Is there a shared proinflammatory network? J. Dtsch. Derm. Ges. 2021, 19, 517–528. | eng |
| dcterms.references | Hedin, C.R.H.; Sonkoly, E.; Eberhardson, M.; Ståhle, M. Inflammatory bowel disease and psoriasis: Modernizing the multidisciplinary approach. J. Intern. Med. 2021, 290, 257–278. | eng |
| dcterms.references | Todberg, T.; Egeberg, A.; Zachariae, C.; Sørensen, N.; Pedersen, O.; Skov, L. Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota. Br. J. Derm. 2022, bjd.21245. | eng |
| dcterms.references | Polak, K.; Bergler-Czop, B.; Szczepanek, M.; Wojciechowska, K.; Frątczak, A.; Kiss, N. Psoriasis and Gut Microbiome-Current State of Art. Int. J. Mol. Sci. 2021, 22, 4529. | eng |
| dcterms.references | Aoun, A.; Darwish, F.; Hamod, N. The Influence of the Gut Microbiome on Obesity in Adults and the Role of Probiotics, Prebiotics, and Synbiotics for Weight Loss. Prev. Nutr. Food Sci. 2020, 25, 113–123. | eng |
| dcterms.references | Muscogiuri, G.; Cantone, E.; Cassarano, S.; Tuccinardi, D.; Barrea, L.; Savastano, S.; Colao, A. Gut microbiota: A new path to treat obesity. Int. J. Obes. Supp. 2019, 9, 10–19. | eng |
| dcterms.references | Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027–1031. | eng |
| dcterms.references | John, G.K.; Mullin, G.E. The Gut Microbiome and Obesity. Curr. Oncol. Rep. 2016, 18, 45. | eng |
| dcterms.references | Lv, Y.; Qin, X.; Jia, H.; Chen, S.; Sun, W.; Wang, X. The association between gut microbiota composition and BMI in Chinese male college students, as analysed by next-generation sequencing. Br. J. Nutr. 2019, 122, 986–995. | eng |
| dcterms.references | Barengolts, E.; Green, S.J.; Chlipala, G.E.; Layden, B.T.; Eisenberg, Y.; Priyadarshini, M.; Dugas, L.R. Predictors of Obesity among Gut Microbiota Biomarkers in African American Men with and without Diabetes. Microorganisms 2019, 7, 320. | eng |
| dcterms.references | Kim, K.N.; Yao, Y.; Ju, S.Y. Short Chain Fatty Acids and Fecal Microbiota Abundance in Humans with Obesity: A Systematic Review and Meta-Analysis. Nutrients 2019, 11, 2512. | eng |
| dcterms.references | Gomes, A.C.; Hoffmann, C.; Mota, J.F. The human gut microbiota: Metabolism and perspective in obesity. Gut. Microbes 2018, 9, 308–325. | eng |
| dcterms.references | Vamanu, E.; Rai, S.N. The Link between Obesity, Microbiota Dysbiosis, and Neurodegenerative Pathogenesis. Diseases 2021, 9, 45. | eng |
| dcterms.references | Olejniczak-Staruch, I.; Ciążyńska, M.; Sobolewska-Sztychny, D.; Narbutt, J.; Skibińska, M.; Lesiak, A. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci. 2021, 22, 3998. | eng |
| dcterms.references | Chen, Y.; Ho, H.J.; Tseng, C.; Lai, Z.; Shieh, J.; Wu, C. Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients. Exp. Derm. 2018, 27, 1336–1343. | eng |
| dcterms.references | Ghezzal, S.; Postal, B.G.; Quevrain, E.; Brot, L.; Seksik, P.; Leturque, A.; Thenet, S.; Carrière, V. Palmitic acid damages gut epithelium integrity and initiates inflammatory cytokine production. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2020, 1865, 158530. | eng |
| dcterms.references | Genser, L.; Aguanno, D.; Soula, H.A.; Dong, L.; Trystram, L.; Assmann, K.; Salem, J.-E.; Vaillant, J.-C.; Oppert, J.-M.; Laugerette, F.; et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. J. Pathol. 2018, 246, 217–230. | eng |
| dcterms.references | Tsai, Y.-W.; Lu, C.-H.; Chang, R.C.-A.; Hsu, Y.-P.; Ho, L.-T.; Shih, K.-C. Palmitoleic acid ameliorates palmitic acid-induced proinflammation in J774A.1 macrophages via TLR4-dependent and TNF-α-independent signallings. Prostaglandins Leukot. Essent. Fat. Acids 2021, 169, 102270. | eng |
| dcterms.references | Zhou, B.; Zhang, J.; Zhang, Q.; Permatasari, F.; Xu, Y.; Wu, D.; Yin, Z.; Luo, D. Palmitic Acid Induces Production of Proinflammatory Cytokines Interleukin-6, Interleukin-1β, and Tumor Necrosis Factor-α via a NF-κB-Dependent Mechanism in HaCaT Keratinocytes. Mediat. Inflamm. 2013, 2013, 530429. | eng |
| dcterms.references | Gong, J.; Campos, H.; McGarvey, S.; Wu, Z.; Goldberg, R.; Baylin, A. Adipose tissue palmitoleic acid and obesity in humans: Does it behave as a lipokine? 123. Am. J. Clin. Nutr. 2011, 93, 186–191. | eng |
| dcterms.references | Bermúdez, V.; Durán, P.; Rojas, E.; Díaz, M.P.; Rivas, J.; Nava, M.; Chacín, M.; Cabrera de Bravo, M.; Carrasquero, R.; Ponce, C.C.; et al. The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium. Front Endocrinol. 2021, 12, 735070. | eng |
| dcterms.references | Sharmin, M.M.; Mizusawa, M.; Hayashi, S.; Arai, W.; Sakata, S.; Yonekura, S. Effects of fatty acids on inducing endoplasmic reticulum stress in bovine mammary epithelial cells. J. Dairy Sci. 2020, 103, 8643–8654. | eng |
| dcterms.references | Ben-Dror, K.; Birk, R. Oleic acid ameliorates palmitic acid-induced ER stress and inflammation markers in naive and cerulein-treated exocrine pancreas cells. Biosci. Rep. 2019, 39, BSR20190054. | eng |
| dcterms.references | Hetz, C. The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 2012, 13, 89–102. | eng |
| dcterms.references | Hetz, C.; Zhang, K.; Kaufman, R.J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 2020, 21, 421–438. | eng |
| dcterms.references | Rozpędek, W.; Pytel, D.; Mucha, B.; Leszczyńska, H.; Diehl, J.A.; Majsterek, I. The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress. Curr. Mol. Med. 2016, 16, 533–544. | eng |
| dcterms.references | Suzuki, T.; Gao, J.; Ishigaki, Y.; Kondo, K.; Sawada, S.; Izumi, T.; Uno, K.; Kaneko, K.; Tsukita, S.; Takahashi, K.; et al. ER Stress Protein CHOP Mediates Insulin Resistance by Modulating Adipose Tissue Macrophage Polarity. Cell Rep. 2017, 18, 2045–2057. | eng |
| dcterms.references | Maya-Monteiro, C.M.; Bozza, P.T. Leptin and mTOR: Partners in metabolism and inflammation. Cell Cycle 2008, 7, 1713–1717. | eng |
| dcterms.references | Cooper, P.O.; Haas, M.R.; Noonepalle, S.K.R.; Shook, B.A. Dermal Drivers of Injury-Induced Inflammation: Contribution of Adipocytes and Fibroblasts. Int. J. Mol. Sci. 2021, 22, 1933. | eng |
| dcterms.references | Rivera-Gonzalez, G.; Shook, B.; Horsley, V. Adipocytes in Skin Health and Disease. Cold Spring Harb. Perspect. Med. 2014, 4, a015271. | eng |
| dcterms.references | Gianfrancesco, M.A.; Dehairs, J.; L’homme, L.; Herinckx, G.; Esser, N.; Jansen, O.; Habraken, Y.; Lassence, C.; Swinnen, J.V.; Rider, M.H.; et al. Saturated fatty acids induce NLRP3 activation in human macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase disruption. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019, 1864, 1017–1030. | eng |
| dcterms.references | Almeida, L.; Everts, B. Fa(c)t checking: How fatty acids shape metabolism and function of macrophages and dendritic cells. Eur. J. Immunol. 2021, 51, 1628–1640. | eng |
| dcterms.references | Stelzner, K.; Herbert, D.; Popkova, Y.; Lorz, A.; Schiller, J.; Gericke, M.; Klöting, N.; Blüher, M.; Franz, S.; Simon, J.C.; et al. Free fatty acids sensitize dendritic cells to amplify TH1/TH17-immune responses. Eur. J. Immunol. 2016, 46, 2043–2053. | eng |
| dcterms.references | Schumann, J. It is all about fluidity: Fatty acids and macrophage phagocytosis. Eur. J. Pharm. 2016, 785, 18–23. | eng |
| dcterms.references | Zhao, M.; Luo, J.; Xiao, B.; Tang, H.; Song, F.; Ding, X.; Yang, G. Endoplasmic reticulum stress links psoriasis vulgaris with keratinocyte inflammation. Postepy Derm. Alergol. 2020, 37, 34–40 | eng |
| dcterms.references | Kanemaru, K.; Matsuyuki, A.; Nakamura, Y.; Fukami, K. Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice. Exp. Derm. 2015, 24, 436–442. | eng |
| dcterms.references | Vasseur, P.; Serres, L.; Jégou, J.-F.; Pohin, M.; Delwail, A.; Petit-Paris, I.; Levillain, P.; Favot, L.; Samson, M.; Yssel, H.; et al. High-Fat Diet-Induced IL-17A Exacerbates Psoriasiform Dermatitis in a Mouse Model of Steatohepatitis. Am. J. Pathol. 2016, 186, 2292–2301. | eng |
| dcterms.references | Klapan, K.; Simon, D.; Karaulov, A.; Gomzikova, M.; Rizvanov, A.; Yousefi, S.; Simon, H.-U. Autophagy and Skin Diseases. Front. Pharmacol. 2022, 13, 380–389. | eng |
| dcterms.references | Chávez-Castillo, M.; Ortega, Á.; Cudris-Torres, L.; Duran, P.; Rojas, M.; Manzano, A.; Garrido, B.; Salazar, J.; Silva, A.; Rojas-Gomez, D.M.; et al. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy? Int. J. Mol. Sci. 2021, 22, 10370. | eng |
| dcterms.references | Basil, M.C.; Levy, B.D. Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 2016, 16, 51–67. | eng |
| dcterms.references | Sugimoto, M.A.; Sousa, L.P.; Pinho, V.; Perretti, M.; Teixeira, M.M. Resolution of Inflammation: What Controls Its Onset? Front. Immunol. 2016, 7, 160. | eng |
| dcterms.references | Fullerton, J.N.; Gilroy, D.W. Resolution of inflammation: A new therapeutic frontier. Nat. Rev. Drug Discov. 2016, 15, 551–567. | eng |
| dcterms.references | Headland, S.E.; Norling, L.V. The resolution of inflammation: Principles and challenges. Semin. Immunol. 2015, 27, 149–160. | eng |
| dcterms.references | Sorokin, A.V.; Domenichiello, A.F.; Dey, A.K.; Yuan, Z.-X.; Goyal, A.; Rose, S.M.; Playford, M.P.; Ramsden, C.E.; Mehta, N.N. Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J. Investig. Derm. 2018, 138, 1518–1528. | eng |
| dcterms.references | Shim, J.H. Prostaglandin E2 Induces Skin Aging via E-Prostanoid 1 in Normal Human Dermal Fibroblasts. Int. J. Mol. Sci. 2019, 20, 5555 | eng |
| dcterms.references | Saito-Sasaki, N.; Sawada, Y.; Nakamura, M. Maresin-1 and Inflammatory Disease. Int. J. Mol. Sci. 2022, 23, 1367 | eng |
| dcterms.references | Krzyszczyk, P.; Schloss, R.; Palmer, A.; Berthiaume, F. The Role of Macrophages in Acute and Chronic Wound Healing and Interventions to Promote Pro-wound Healing Phenotypes. Front Physiol. 2018, 9, 419. | eng |
| dcterms.references | Wang, W.; Xu, R.-L.; He, P.; Chen, R. MAR1 suppresses inflammatory response in LPS-induced RAW 264.7 macrophages and human primary peripheral blood mononuclear cells via the SIRT1/PGC-1α/PPAR-γ pathway. J. Inflamm. 2021, 18, 8. | eng |
| dcterms.references | Chiurchiù, V.; Leuti, A.; Dalli, J.; Jacobsson, A.; Battistini, L.; Maccarrone, M.; Serhan, C.N. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci. Transl. Med. 2016, 8, 353ra111. | eng |
| dcterms.references | Sasaki-Saito, N.; Sawada, Y.; Nakamura, M. 954 Maresin-1 inhibits IL-23 receptors via down-regulation of RORt expression and internalization in an imiquimod-induced psoriasis model mouse. J. Investig. Derm. 2018, 138, S162 | eng |
| dcterms.references | Abdulnour, R.-E.E.; Dalli, J.; Colby, J.K.; Krishnamoorthy, N.; Timmons, J.Y.; Tan, S.H.; Colas, R.A.; Petasis, N.A.; Serhan, C.N.; Levy, B.D. Maresin 1 biosynthesis during platelet–neutrophil interactions is organ-protective. Proc. Natl. Acad. Sci. USA 2014, 111, 16526–16531. | eng |
| dcterms.references | Saito-Sasaki, N.; Sawada, Y.; Mashima, E.; Yamaguchi, T.; Ohmori, S.; Yoshioka, H.; Haruyama, S.; Okada, E.; Nakamura, M. Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression. Sci. Rep. 2018, 8, 5522. | eng |
| dcterms.references | Fania, L.; Morelli, M.; Scarponi, C.; Mercurio, L.; Scopelliti, F.; Cattani, C.; Scaglione, G.L.; Tonanzi, T.; Pilla, M.A.; Pagnanelli, G.; et al. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development. J. Pathol. Clin. Res. 2020, 6, 55–68. | eng |
| dcterms.references | Yunanto, K.A.; Waspodo, N.N.; Tabri, F.; Ilyas, F. Obesity as a comorbid factor in a boy with psoriasis vulgaris. Enfermería Clínica 2020, 30, 259–262. | eng |
| dcterms.references | Griffiths, C.E.; Barker, J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370, 263–271. | eng |
| dcterms.references | Hugh, J.M.; Weinberg, J.M. Update on the pathophysiology of psoriasis. Cutis 2018, 102, 6–12. | eng |
| dcterms.references | Grän, F.; Kerstan, A.; Serfling, E.; Goebeler, M.; Muhammad, K. Current Developments in the Immunology of Psoriasis. Yale J. Biol. Med. 2020, 93, 97–110. | eng |
| dcterms.references | Hwang, J.; Yoo, J.A.; Yoon, H.; Han, T.; Yoon, J.; An, S.; Cho, J.Y.; Lee, J. The Role of Leptin in the Association between Obesity and Psoriasis. Biomol. Ther. 2021, 29, 11–21. | eng |
| dcterms.references | Thomas, J.; Küpper, M.; Batra, R.; Jargosch, M.; Atenhan, A.; Baghin, V.; Krause, L.; Lauffer, F.; Biedermann, T.; Theis, F.J.; et al. Is the humoral immunity dispensable for the pathogenesis of psoriasis? J. Eur. Acad. Derm. Venereol. 2019, 33, 115–122. | eng |
| dcterms.references | Kyriakou, A.; Patsatsi, A.; Sotiriadis, D.; Goulis, D.G. Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies. Dermatology 2017, 233, 378–389. | eng |
| dcterms.references | Yeung, H.; Takeshita, J.; Mehta, N.N.; Kimmel, S.E.; Ogdie, A.; Margolis, D.J.; Shin, D.B.; Attor, R.; Troxel, A.B.; Gelfand, J.M. Psoriasis Severity and the Prevalence of Major Medical Comorbidity: A Population-Based Study. JAMA Derm. 2013, 149, 1173–1179. | eng |
| dcterms.references | Gupta, S.; Syrimi, Z.; Hughes, D.M.; Zhao, S.S. Comorbidities in psoriatic arthritis: A systematic review and meta-analysis. Rheumatol. Int. 2021, 41, 275–284. | eng |
| dcterms.references | Hile, G.; Kahlenberg, J.M.; Gudjonsson, J.E. Recent genetic advances in innate immunity of psoriatic arthritis. Clin. Immunol. 2020, 214, 108405. | eng |
| dcterms.references | Ben Abdallah, H.; Johansen, C.; Iversen, L. Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis Targets Ther. 2021, 11, 83–97. | eng |
| dcterms.references | Storer, M.A.; Danesh, M.J.; Sandhu, M.E.; Pascoe, V.; Kimball, A.B. An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. Int. J. Womens Dermatol. 2018, 4, 198–202. | eng |
| dcterms.references | Salihbegovic, E.M.; Kurtalic, S.; Omerkic, E. Comorbidity in Men with Psoriasis. Med. Arch. 2021, 75, 31–34. | eng |
| dcterms.references | Higgins, E. Psoriasis. Medicine 2021, 49, 361–369. | eng |
| dcterms.references | Shi, L.-Q.; Lian, N.; Sun, J.-T.; Liu, L.-H.; Chen, M. Association between the systemic treatment of psoriasis and cardiovascular risk. Chin. Med. J. 2021, 134, 518–520. | eng |
| dcterms.references | Jacobi, A.; Langenbruch, A.; Purwins, S.; Augustin, M.; Radtke, M.A. Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3. Dermatology 2015, 231, 231–238. | eng |
| dcterms.references | Shah, S.; Nikam, B.; Kale, M.; Jamale, V.; Chavan, D. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study. Dermatol. Ther. 2021, 34, e14650. | eng |
| dcterms.references | Ghoreschi, K.; Balato, A.; Enerbäck, C.; Sabat, R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021, 397, 754–766. | eng |
| dcterms.references | Mylonas, A.; Conrad, C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front. Immunol. 2018, 9, 2746. | eng |
| dcterms.references | Le, S.T.; Toussi, A.; Maverakis, N.; Marusina, A.I.; Barton, V.R.; Merleev, A.A.; Luxardi, G.; Raychaudhuri, S.P.; Maverakis, E. The cutaneous and intestinal microbiome in psoriatic disease. Clin. Immunol. 2020, 218, 108537. | eng |
| dcterms.references | Guo, Z.; Yang, Y.; Liao, Y.; Shi, Y.; Zhang, L. Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity. JID Innov. 2022, 2, 100064. | eng |
| dcterms.references | Hsu, D.K.; Fung, M.A.; Chen, H.-L. Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease. Med. Microecol. 2020, 4, 100016. | eng |
| dcterms.references | Szántó, M.; Dózsa, A.; Antal, D.; Szabó, K.; Kemény, L.; Bai, P. Targeting the gut-skin axis—Probiotics as new tools for skin disorder management? Exp. Derm. 2019, 28, 1210–1218. | eng |
| dcterms.references | Thye, A.Y.-K.; Bah, Y.-R.; Law, J.W.-F.; Tan, L.T.-H.; He, Y.-W.; Wong, S.-H.; Thurairajasingam, S.; Chan, K.-G.; Lee, L.-H.; Letchumanan, V. Gut–Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis. Biomedicines 2022, 10, 1037. | eng |
| dcterms.references | Chen, Y.-H.; Wu, C.-S.; Chao, Y.-H.; Lin, C.-C.; Tsai, H.-Y.; Li, Y.-R.; Chen, Y.-Z.; Tsai, W.-H.; Chen, Y.-K. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J. Food Drug Anal. 2017, 25, 559–566. | eng |
| dcterms.references | Thio, H.B. The Microbiome in Psoriasis and Psoriatic Arthritis: The Skin Perspective. J. Rheumatol. 2018, 94, 30–31. | eng |
| dcterms.references | Vijayashankar, M.; Raghunath, N. Pustular psoriasis responding to Probiotics—A new insight. Our Derm. Online 2012, 3, 326–329. | eng |
| dcterms.references | Groeger, D.; O’Mahony, L.; Murphy, E.F.; Bourke, J.F.; Dinan, T.G.; Kiely, B.; Shanahan, F.; Quigley, E.M.M. Bifidobacterium infantis 35,624 modulates host inflammatory processes beyond the gut. Gut. Microbes. 2013, 4, 325–339. | eng |
| dcterms.references | Lin, C.; Zeng, T.; Deng, Y.; Yang, W.; Xiong, J. [Treatment of psoriasis vulgaris using Bacteroides fragilis BF839: A single-arm, open preliminary clinical study]. Sheng Wu Gong Cheng Xue Bao 2021, 37, 3828–3835. | eng |
| dcterms.references | Carrara, M.; Kelly, M.T.; Roso, F.; Larroque, M.; Margout, D. Potential of Olive Oil Mill Wastewater as a Source of Polyphenols for the Treatment of Skin Disorders: A Review. J. Agric. Food Chem. 2021, 69, 7268–7284. | eng |
| dcterms.references | Medina, M. Tratamiento Alternativo al Uso Crónico de Esteroides e Inmunosupresores en Psoriasis Mediante Polifenoles Aislados del Aceite Del Oliva. Ph.D. Thesis, Universidad del Zulia, Maracaibo, Venezuela. | spa |
| dcterms.references | Medina, M.; Cano, R.; Contreras, I.; Prado, A.; Cano, C. Estudio comparativo de la eficiencia terapéutica entre imiquimod crema al 5% y una loción basada en polifenoles en el tratamiento de la queratosis actínica. Arch. Venez. Farmacol. Ter. 2015, 34, 16–20. | spa |
| dcterms.references | Yan, D.; Blauvelt, A.; Dey, A.K.; Golpanian, R.S.; Hwang, S.T.; Mehta, N.N.; Myers, B.; Shi, Z.; Yosipovitch, G.; Bell, S.; et al. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. J. Investig. Dermatol. 2021, 141, 2328–2337. | eng |
| dcterms.references | Griffiths, C.E.M.; Armstrong, A.W.; Gudjonsson, J.E.; Barker, J.N.W.N. Psoriasis. Lancet 2021, 397, 1301–1315. | eng |
| dcterms.references | Pirro, F.; Caldarola, G.; Chiricozzi, A.; Burlando, M.; Mariani, M.; Parodi, A.; Peris, K.; De Simone, C. Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. Clin. Drug Investig. 2021, 41, 917–925. | eng |
| dcterms.references | Su, X.; Zhang, G.; Cheng, Y.; Wang, B. Leptin in skin disease modulation. Clin. Chim. Acta 2021, 516, 8–14. | eng |
| dcterms.references | Madden, S.K.; Flanagan, K.L.; Jones, G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clin. Nutr. 2020, 39, 1026–1040. | eng |
| dcterms.references | Villarreal-Calderón, J.R.; Cuéllar, R.X.; Ramos-González, M.R.; Rubio-Infante, N.; Castillo, E.C.; Elizondo-Montemayor, L.; García-Rivas, G. Interplay between the Adaptive Immune System and Insulin Resistance in Weight Loss Induced by Bariatric Surgery. Oxidative Med. Cell. Longev. 2019, 2019, 1–14. | eng |
| dcterms.references | Maglio, C.; Peltonen, M.; Rudin, A.; Carlsson, L.M.S. Bariatric Surgery and the Incidence of Psoriasis and Psoriatic Arthritis in the Swedish Obese Subjects Study: Effect of Bariatric Surgery on Psoriasis. Obesity 2017, 25, 2068–2073. | eng |
| dcterms.references | Egeberg, A.; Sørensen, J.A.; Gislason, G.H.; Knop, F.K.; Skov, L. Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery. JAMA Surg. 2017, 152, 344. | eng |
| dcterms.references | Farias, M.M.; Achurra, P.; Boza, C.; Vega, A.; de la Cruz, C. Psoriasis following bariatric surgery: Clinical evolution and impact on quality of life on 10 patients. Obes. Surg. 2012, 22, 877–880. | eng |
| dcterms.references | Alruwaili, H.; Dehestani, B.; le Roux, C.W. Clinical Impact of Liraglutide as a Treatment of Obesity. CPAA 2021, 13, 53–60. | eng |
| dcterms.references | Wilding, J.P.H.; Batterham, R.L.; Calanna, S.; Davies, M.; Van Gaal, L.F.; Lingvay, I.; McGowan, B.M.; Rosenstock, J.; Tran, M.T.D.; Wadden, T.A.; et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 2021, 384, 989–1002. | eng |
| dcterms.references | Zobel, E.H.; Ripa, R.S.; von Scholten, B.J.; Rotbain Curovic, V.; Kjaer, A.; Hansen, T.W.; Rossing, P.; Størling, J. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Sci. Rep. 2021, 11, 18522. | eng |
| dcterms.references | Chang, G.; Chen, B.; Zhang, L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: A systematic review and meta-analysis of prospective cohort and before-after studies. J. Dermatol. Treat. 2022, 33, 1299–1305. | eng |
| dcterms.references | Xu, X.; Lin, L.; Chen, P.; Yu, Y.; Chen, S.; Chen, X.; Shao, Z. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res. Clin. Pract. 2019, 150, 167–173. | eng |
| dcterms.references | Lin, L.; Xu, X.; Yu, Y.; Ye, H.; He, X.; Chen, S.; Chen, X.; Shao, Z.; Chen, P. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: A randomized-controlled trial. J. Dermatol. Treat. 2022, 33, 1428–1434 | eng |
| dcterms.references | Costanzo, G.; Curatolo, S.; Busà, B.; Belfiore, A.; Gullo, D. Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol. Diabetes Metab. Case Rep. 2021, 2021. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | eng |